about
Do studies reporting 'U'-shaped serum 25-hydroxyvitamin D-health outcome relationships reflect adverse effects?The seasonality of pandemic and non-pandemic influenzas: the roles of solar radiation and vitamin D.Photosensitizing effect of protoporphyrin IX in pigmented melanoma of mice.Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy.Photostability of commercial sunscreens upon sun exposure and irradiation by ultraviolet lamps.Milestones in the development of photodynamic therapy and fluorescence diagnosis.Influence of formulation factors on PpIX production and photodynamic action of novel ALA-loaded microparticles.Bioimpedance for pain monitoring during cutaneous photodynamic therapy: Preliminary study.Fluorescence photobleaching of ALA and ALA-heptyl ester induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: a comparison of two light sources and different illumination schemes.Seasonal variations of cancer incidence and prognosis.Time trends and latitude dependence of uveal and cutaneous malignant melanoma induced by solar radiation.Influenza, solar radiation and vitamin D.Development of different human skin colors: a review highlighting photobiological and photobiophysical aspects.Photodynamic therapy of cancer: an updateOn the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation.Erythrocytes-the 'house elves' of photodynamic therapy.Biophysical aspects of photodynamic therapy.Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy?Biologically efficient solar radiation: Vitamin D production and induction of cutaneous malignant melanoma.North-South gradients of melanomas and non-melanomas: A role of vitamin D?Review Article: Health benefit of increased serum 25(OH)D levels from oral intake and ultraviolet-B irradiance in the Nordic countries.Vitamin D, sun, sunbeds and health.Beneficial effects of UV radiation other than via vitamin D production.The history of PDT in Norway Part one: Identification of basic mechanisms of general PDT.The history of PDT in Norway Part II. Recent advances in general PDT and ALA-PDT.Sun exposure and melanomas on sun-shielded and sun-exposed body areas.Supramolecular nanoscale assemblies for cancer diagnosis and therapy.Folic acid and its photoproducts, 6-formylpterin and pterin-6-carboxylic acid, as generators of reactive oxygen species in skin cells during UVA exposure.Phototherapy and vitamin D.Immediate pigment darkening: its evolutionary roles may include protection against folate photosensitization.Sunbed use and cutaneous melanoma in Norway.Metabolic-targeted therapy with dichloroacetate (DCA): a novel treatment strategy to improve the outcome of photodynamic therapy.Application of 5-aminolevulinic acid and its derivatives for photodynamic therapy in vitro and in vivo.Diamino acid derivatives of PpIX as potential photosensitizers for photodynamic therapy of squamous cell carcinoma and prostate cancer: in vitro studies.Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy.In vitro and in vivo photosensitization by protoporphyrins possessing different lipophilicities and vertical localization in the membrane.The influence of temperature on photodynamic cell killing in vitro with 5-aminolevulinic acid.Daily, seasonal, and latitudinal variations in solar ultraviolet A and B radiation in relation to vitamin D production and risk for skin cancer.Deferoxamine photosensitizes cancer cells in vitro.Influence of multiple UV exposures on serum cobalamin and vitamin D levels in healthy females.
P50
Q26739511-A28A41B1-04CB-4493-9D39-94C54F37C751Q30395588-34CF5887-499F-450C-8325-0B209FB2E81CQ31110412-EFDCF20E-F155-41B9-83FF-3A60E642C76EQ33208230-46E77F92-2DD3-499D-9E26-A7E12EE64F03Q33275604-4BB7EC16-D186-42C8-8704-3F107B7F46D2Q33307700-CB16D7EC-5B70-4D80-9EB1-34D5242611B6Q33410442-36F30245-3CCC-43F0-AAF9-FB0294B35FDAQ34084876-0B08D59E-4FCF-4DE5-9EC6-E90A94C2499CQ34086110-3BBF3ECA-874A-4E80-994C-A1727C626D0FQ34847240-BF882198-5EC0-4CEA-9FE5-6A78007D20BFQ34890998-322589AE-0789-4511-BF12-6BDA8EB99C16Q34974621-493953D9-349C-41BB-BEA9-92102F9D8854Q34983955-1D2BAEA5-B647-4B32-8F9A-9408C8CAE3A6Q35532394-E29D2565-A427-4175-BB27-3287959C7292Q35768359-FDD035FE-89A5-4E77-B0E0-D5BD25DB111FQ35966814-2DC6B4C0-129B-4305-91B9-85E5D9F1912AQ36432731-A7D8BA83-20D5-4D2B-8B7D-F67913FF89F2Q37255029-D984C23B-4F32-4E71-B6EC-120BE1F5FC4CQ37499923-398828CA-03A1-4E01-8659-21AAAF5AF1AAQ37499943-801D6EFC-BDE6-4EFF-81F3-5DAB6D2E98F7Q37785398-BF63A610-6426-435B-9F37-4456BE735A72Q37948188-AFDB57EC-8A86-451E-A1A3-E9B65219084FQ38038605-C48C991A-9637-4DA5-B01E-8A5DB4EB44F1Q38232262-3AC6CC53-05A3-4399-BB85-8361E77067E6Q38232285-D6E0CD33-8959-4AE4-A06D-1AF4D4A2CC51Q38248046-AC8A2088-807C-4B0B-A409-F3F92CAB9E0EQ38544651-7F2D90E5-E7C4-4656-8410-FCE7A2275047Q38802330-7712B1C9-6323-4D84-A0EB-AC01E69392CCQ38957161-1F510E67-37E4-4628-8E27-81362E9EA2BBQ39256839-07CFF63E-C5ED-494B-B575-6787E13FCFA9Q39373906-A6C187A6-81B3-4929-910F-EBC5B63F93DFQ39639436-69A394D8-6C7C-41E6-8D90-A0FB6D6C6207Q39692414-990371D8-B734-4D00-B44E-E4E42A62393BQ39896743-519D15DE-B2C6-4FD1-A5AE-D3791C4ECC59Q39942849-24BE0981-121D-474C-A4A4-8A2687AB9C1FQ40272988-1B827E12-A8DB-4BF0-9281-3049E9AC134EQ40290244-4DFFC7E5-B588-42DC-BD98-A401974866EEQ40345681-24CABFDC-02CB-4482-94AC-04D2B85D00F8Q40418601-A9E49873-4F69-4476-9822-0D4A630EF5C8Q41294068-106749BB-752E-4225-9CA8-86B1823B653A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Asta Juzeniene
@ast
Asta Juzeniene
@en
Asta Juzeniene
@es
Asta Juzeniene
@nl
type
label
Asta Juzeniene
@ast
Asta Juzeniene
@en
Asta Juzeniene
@es
Asta Juzeniene
@nl
prefLabel
Asta Juzeniene
@ast
Asta Juzeniene
@en
Asta Juzeniene
@es
Asta Juzeniene
@nl
P106
P1153
6603543055
P21
P31
P496
0000-0001-9426-0062